Developer docs
API playgroundTry for free, no card

Search company profiles

AmplifiDx

Full company profile

uuid0003dai

Namestring
AmplifiDx
Legal namestring
AmplifiDx, Inc.
Websiteurl
amplifidx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

AmplifiDx is a privately held point-of-care molecular diagnostics company founded in 2020 and headquartered in Newark, California, with a secondary office in Waltham, Massachusetts. The company is developing the DX 100 Platform, a compact nucleic acid amplification testing (NAAT) system designed to deliver multiplexed infectious disease detection (up to 10 analytes simultaneously) in under 20 minutes with less than one minute of hands-on time. The platform's clinical performance was validated in a study of the first-generation DX 1000 System running the AmplifiDx COVID-19 Assay, demonstrating 97.8% positive percent agreement and 100% negative percent agreement against the Roche cobas Liat PCR comparator. All products remain under development and are not yet cleared or approved by the FDA.

The intended assay menu spans respiratory pathogens via the RespiFast Test (SARS-CoV-2, Influenza A/B, RSV) and a pipeline of sexual and women's health tests including STI NG Plus, SYPHony (syphilis), iVAGine, and CerviGARD (cervical health screening). The business model is structured as a razor-and-blade — placement of the DX 100 instrument paired with recurring single-use assay cartridge sales — targeting community and rural health clinics, physician offices, urgent care centers, and women's/sexual health providers seeking test-to-treat workflows within a single patient visit. Go-to-market is sales-led and direct to U.S. healthcare facilities. The company has assembled a four-person C-suite (CEO Nancy Schoenbrunner, CSO Shoulian Dong, CPO Daniel Schoener, CCO Chris Meda) and operates with a headcount of 1–10.

Financially, AmplifiDx has been funded primarily through non-dilutive NIH Rapid Acceleration of Diagnostics (RADx) Tech grants totaling $4.51 million (initial $1.38M award in May 2023 and $954,213 in December 2024), supplemented by an approximately $1.8 million seed round in January 2022 from SeedFolio, Social Starts, and Titan Angels, and additional smaller tranches. The company has not generated commercial revenue and remains pre-FDA. Its strategic posture is to leverage multiplex accuracy and POC usability to compete in the test-to-treat diagnostics category against established players such as Cepheid, Abbott ID NOW, and Roche cobas Liat, with a differentiated focus on women's and sexual health applications.

Short descriptiontext

AmplifiDx is a privately held point-of-care molecular diagnostics company developing the DX 100 NAAT platform and a menu of respiratory, sexual, and women's health assays targeting community clinics, physician offices, urgent care centers, and women's health providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, point-of-care testing, infectious disease detection, NAAT technology, rapid diagnostics
Industry2 codes
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Platform Hardware
TypeHardware Sales
Description

Sale of the DX 100 instrument system to healthcare providers including clinics, physician offices, and urgent care centers.

amplifidx.com
2Diagnostic Assay Consumables
TypeOne Time License
Description

Single-use test cartridges and assays for the DX 100 Platform including RespiFast, STI NG Plus, iVAGine, SYPHony, and CerviGARD tests.

amplifidx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1DX 100 Platform
Description

Point-of-care molecular diagnostic platform that detects up to 10 analytes simultaneously, providing results in under 20 minutes with less than 1 minute hands-on time.

amplifidx.com
+5 more records
Core offering1 text field

AmplifiDx develops and sells a point-of-care molecular diagnostic platform (DX 100) and a portfolio of single-use assay cartridges for infectious disease detection. The platform delivers PCR-grade accuracy in under 20 minutes with less than one minute of hands-on time and can detect up to 10 analytes simultaneously from a single sample. Target users are healthcare providers in community clinics, physician offices, and urgent care centers; products are not yet FDA cleared or approved.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 97.8% Positive Percent Agreement (PPA) and 100% Negative Percent Agreement (NPA) compared to Roche cobas Liat PCR system
+3 more records
Product overview1 text field

AmplifiDx offers a unified platform-plus-assays portfolio centered on the DX 100™ Platform, a point-of-care molecular diagnostic system. The platform enables rapid multiplex testing (up to 10 analytes per test) with results in under 20 minutes and less than one minute hands-on time. Currently marketed and developing assays include: RespiFast™ (respiratory pathogens: SARS-CoV-2, Flu A/B, RSV), STI NG Plus™ (sexual health), SYPHony™ (syphilis), iVAGine™ (women's health), and CerviGARD™ (women's/cervical health). The company also developed the AmplifiDx COVID-19 Assay™ for the first-generation DX 1000 System™. All products are not yet cleared or approved by the FDA.

Product and service8 records
1DX 100 Platform
CategoryDiagnostic Platform Hardware
Description

Point-of-care molecular diagnostic instrument platform delivering fast, accurate results in under 20 minutes with less than one minute of hands-on time. Detects up to 10 analytes simultaneously and is designed for healthcare providers in community clinics, physician offices, and urgent care centers.

2RespiFast Test
CategoryDiagnostic Assay Consumable
Description

Single-use molecular point-of-care assay cartridge for the DX 100 Platform that detects and differentiates SARS-CoV-2, Influenza A, Influenza B, and RSV, delivering results within 20 minutes to support immediate treatment decisions.

3AmplifiDx COVID-19 Assay
CategoryDiagnostic Assay Consumable
Description

Molecular diagnostic assay for SARS-CoV-2 detection, validated on the first-generation DX 1000 System with 97.8% positive percent agreement and 100% negative percent agreement compared to the Roche cobas liat PCR comparator.

4DX 1000 System
CategoryDiagnostic Platform Hardware
Description

First-generation molecular diagnostic instrument used in clinical studies validating the AmplifiDx COVID-19 Assay and reporting 97.8% PPA and 100% NPA versus the Roche cobas liat comparator.

5STI NG Plus
CategoryDiagnostic Assay Consumable
Description

Sexually transmitted infection multiplex test in development on the DX 100 Platform, intended to expand the company's sexual health diagnostics menu at the point of care.

6iVAGine
CategoryDiagnostic Assay Consumable
Description

Women's health point-of-care diagnostic test in development on the DX 100 Platform, leveraging the platform's multiplex detection capability.

7SYPHony
CategoryDiagnostic Assay Consumable
Description

Syphilis diagnostic test in development on the DX 100 Platform, part of the sexual health testing portfolio targeting point-of-care screening and treatment initiation.

8CerviGARD
CategoryDiagnostic Assay Consumable
Description

Cervical health screening test in development on the DX 100 Platform, intended to extend women's health diagnostics into point-of-care cervical screening workflows.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

QIAstat-Dx is a multiplex molecular POC platform for respiratory and other syndromic panels, directly comparable to AmplifiDx's multiplex NAAT approach in target customers and menu strategy.

TypeDirect peer
Description

BioFire FilmArray is a multiplex syndromic molecular testing platform used in clinical settings; AmplifiDx's 10-plex NAAT ambition for respiratory, STI, and women's health panels directly competes with FilmArray's multiplexing value proposition.

TypeEmerging player
Description

Visby offers a single-use, instrument-free PCR device for STI and infectious disease testing at POC; a relevant emerging competitor demonstrating both the opportunity and capital intensity of the molecular POC market.

4Abbott
TypeBroad incumbent
Description

Abbott's ID NOW is an established isothermal molecular POC platform with broad clinic penetration; a direct head-to-head competitor for rapid, instrument-based molecular infectious disease testing at the point of care.

5Cue Health
TypeEmerging player
Description

Cue developed a connected molecular POC COVID/flu test for consumer and clinical use; a similarly positioned emerging molecular POC company competing for the same decentralized testing narrative.

6Talis Biomedical
TypeEmerging player
Description

Talis pursued a cartridge-based molecular POC platform for infectious disease testing; useful as a peer showing the development, regulatory, and commercialization challenges facing AmplifiDx's category.

TypeBroad incumbent
Description

Roche's cobas Liat system is the named PCR comparator in AmplifiDx's clinical study and a leading molecular POC platform, making Roche the most directly relevant incumbent benchmark for performance, scale, and FDA-cleared distribution.

TypeOthers
Description

Mesa Labs provides quality control, calibration, and proficiency testing materials for IVD workflows; adjacent infrastructure supplier relevant to AmplifiDx's IVD consumables business model.

TypeBroad incumbent
Description

QuidelOrtho's Sofia and Savanna platforms span rapid immunoassay and molecular POC diagnostics; a broad incumbent with established CLIA-waived channels that AmplifiDx would need to dislodge.

TypeDirect peer
Description

GeneXpert is the dominant molecular POC/CLIA-waived NAAT system deployed across clinics and hospitals globally; AmplifiDx targets the same NAAT-POC workflows with a more compact, lower-cost, multiplex-focused instrument.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AmplifiDx

Molecular Diagnosticsamplifidx.com

AmplifiDx is a privately held point-of-care molecular diagnostics company developing the DX 100 NAAT platform and a menu of respiratory, sexual, and women's health assays targeting community clinics, physician offices, urgent care centers, and women's health providers.

What AmplifiDx does

AmplifiDx is a privately held point-of-care molecular diagnostics company founded in 2020 and headquartered in Newark, California, with a secondary office in Waltham, Massachusetts. The company is developing the DX 100 Platform, a compact nucleic acid amplification testing (NAAT) system designed to deliver multiplexed infectious disease detection (up to 10 analytes simultaneously) in under 20 minutes with less than one minute of hands-on time. The platform's clinical performance was validated in a study of the first-generation DX 1000 System running the AmplifiDx COVID-19 Assay, demonstrating 97.8% positive percent agreement and 100% negative percent agreement against the Roche cobas Liat PCR comparator. All products remain under development and are not yet cleared or approved by the FDA.

The intended assay menu spans respiratory pathogens via the RespiFast Test (SARS-CoV-2, Influenza A/B, RSV) and a pipeline of sexual and women's health tests including STI NG Plus, SYPHony (syphilis), iVAGine, and CerviGARD (cervical health screening). The business model is structured as a razor-and-blade — placement of the DX 100 instrument paired with recurring single-use assay cartridge sales — targeting community and rural health clinics, physician offices, urgent care centers, and women's/sexual health providers seeking test-to-treat workflows within a single patient visit. Go-to-market is sales-led and direct to U.S. healthcare facilities. The company has assembled a four-person C-suite (CEO Nancy Schoenbrunner, CSO Shoulian Dong, CPO Daniel Schoener, CCO Chris Meda) and operates with a headcount of 1–10.

Financially, AmplifiDx has been funded primarily through non-dilutive NIH Rapid Acceleration of Diagnostics (RADx) Tech grants totaling $4.51 million (initial $1.38M award in May 2023 and $954,213 in December 2024), supplemented by an approximately $1.8 million seed round in January 2022 from SeedFolio, Social Starts, and Titan Angels, and additional smaller tranches. The company has not generated commercial revenue and remains pre-FDA. Its strategic posture is to leverage multiplex accuracy and POC usability to compete in the test-to-treat diagnostics category against established players such as Cepheid, Abbott ID NOW, and Roche cobas Liat, with a differentiated focus on women's and sexual health applications.

AmplifiDx firmographics

Firmographics
Name
AmplifiDx
Legal name
AmplifiDx, Inc.
Website
https://amplifidx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
AmplifiDx is a privately held point-of-care molecular diagnostics company developing the DX 100 NAAT platform and a menu of respiratory, sexual, and women's health assays targeting community clinics, physician offices, urgent care centers, and women's health providers.
Ownership category
akta.pro rank

AmplifiDx industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostics
  • Point-of-care testing
  • Infectious disease detection
  • NAAT technology
  • Rapid diagnostics

Where AmplifiDx is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AmplifiDx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Diagnostic Platform Hardware: Sale of the DX 100 instrument system to healthcare providers including clinics, physician offices, and urgent care centers.
  2. Diagnostic Assay Consumables: Single-use test cartridges and assays for the DX 100 Platform including RespiFast, STI NG Plus, iVAGine, SYPHony, and CerviGARD tests.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

AmplifiDx product offering

Product offering

Core offering

AmplifiDx develops and sells a point-of-care molecular diagnostic platform (DX 100) and a portfolio of single-use assay cartridges for infectious disease detection. The platform delivers PCR-grade accuracy in under 20 minutes with less than one minute of hands-on time and can detect up to 10 analytes simultaneously from a single sample. Target users are healthcare providers in community clinics, physician offices, and urgent care centers; products are not yet FDA cleared or approved.

Product overview

AmplifiDx offers a unified platform-plus-assays portfolio centered on the DX 100™ Platform, a point-of-care molecular diagnostic system. The platform enables rapid multiplex testing (up to 10 analytes per test) with results in under 20 minutes and less than one minute hands-on time. Currently marketed and developing assays include: RespiFast™ (respiratory pathogens: SARS-CoV-2, Flu A/B, RSV), STI NG Plus™ (sexual health), SYPHony™ (syphilis), iVAGine™ (women's health), and CerviGARD™ (women's/cervical health). The company also developed the AmplifiDx COVID-19 Assay™ for the first-generation DX 1000 System™. All products are not yet cleared or approved by the FDA.

Differentiator

Problem solved

Functional benefit

Brands

  • DX 100 Platform: Point-of-care molecular diagnostic platform that detects up to 10 analytes simultaneously, providing results in under 20 minutes with less than 1 minute hands-on time.
  • RespiFast Test
  • STI NG Plus
  • iVAGine
  • SYPHony
  • CerviGARD

Products and services

  • DX 100 Platform Point-of-care molecular diagnostic instrument platform delivering fast, accurate results in under 20 minutes with less than one minute of hands-on time. Detects up to 10 analytes simultaneously and is designed for healthcare providers in community clinics, physician offices, and urgent care centers.
  • RespiFast Test Single-use molecular point-of-care assay cartridge for the DX 100 Platform that detects and differentiates SARS-CoV-2, Influenza A, Influenza B, and RSV, delivering results within 20 minutes to support immediate treatment decisions.
  • AmplifiDx COVID-19 Assay Molecular diagnostic assay for SARS-CoV-2 detection, validated on the first-generation DX 1000 System with 97.8% positive percent agreement and 100% negative percent agreement compared to the Roche cobas liat PCR comparator.
  • DX 1000 System First-generation molecular diagnostic instrument used in clinical studies validating the AmplifiDx COVID-19 Assay and reporting 97.8% PPA and 100% NPA versus the Roche cobas liat comparator.
  • STI NG Plus Sexually transmitted infection multiplex test in development on the DX 100 Platform, intended to expand the company's sexual health diagnostics menu at the point of care.
  • iVAGine Women's health point-of-care diagnostic test in development on the DX 100 Platform, leveraging the platform's multiplex detection capability.
  • SYPHony Syphilis diagnostic test in development on the DX 100 Platform, part of the sexual health testing portfolio targeting point-of-care screening and treatment initiation.
  • CerviGARD Cervical health screening test in development on the DX 100 Platform, intended to extend women's health diagnostics into point-of-care cervical screening workflows.

Quantifiable outcome

  • 97.8% Positive Percent Agreement (PPA) and 100% Negative Percent Agreement (NPA) compared to Roche cobas Liat PCR system
  • +3 more outcomes

Companies that use AmplifiDx

Customer profile

Segments5 records

Ideal customer profiles3 records

AmplifiDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AmplifiDx partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

AmplifiDx competitors and assessment

Company assessment

Direct peers

  • Qiagen: QIAstat-Dx is a multiplex molecular POC platform for respiratory and other syndromic panels, directly comparable to AmplifiDx's multiplex NAAT approach in target customers and menu strategy.
  • BioMérieux: BioFire FilmArray is a multiplex syndromic molecular testing platform used in clinical settings; AmplifiDx's 10-plex NAAT ambition for respiratory, STI, and women's health panels directly competes with FilmArray's multiplexing value proposition.
  • Cepheid (Danaher): GeneXpert is the dominant molecular POC/CLIA-waived NAAT system deployed across clinics and hospitals globally; AmplifiDx targets the same NAAT-POC workflows with a more compact, lower-cost, multiplex-focused instrument.

Emerging players

  • Visby Medical: Visby offers a single-use, instrument-free PCR device for STI and infectious disease testing at POC; a relevant emerging competitor demonstrating both the opportunity and capital intensity of the molecular POC market.
  • Cue Health: Cue developed a connected molecular POC COVID/flu test for consumer and clinical use; a similarly positioned emerging molecular POC company competing for the same decentralized testing narrative.
  • Talis Biomedical: Talis pursued a cartridge-based molecular POC platform for infectious disease testing; useful as a peer showing the development, regulatory, and commercialization challenges facing AmplifiDx's category.

Broad incumbents

  • Abbott: Abbott's ID NOW is an established isothermal molecular POC platform with broad clinic penetration; a direct head-to-head competitor for rapid, instrument-based molecular infectious disease testing at the point of care.
  • Roche Diagnostics: Roche's cobas Liat system is the named PCR comparator in AmplifiDx's clinical study and a leading molecular POC platform, making Roche the most directly relevant incumbent benchmark for performance, scale, and FDA-cleared distribution.
  • QuidelOrtho: QuidelOrtho's Sofia and Savanna platforms span rapid immunoassay and molecular POC diagnostics; a broad incumbent with established CLIA-waived channels that AmplifiDx would need to dislodge.

Others

  • Mesa Labs: Mesa Labs provides quality control, calibration, and proficiency testing materials for IVD workflows; adjacent infrastructure supplier relevant to AmplifiDx's IVD consumables business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AmplifiDx social profiles

Digital presence

AmplifiDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AmplifiDx leadership team

Management profile

Number of profiles

Profiles4 records

AmplifiDx funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AmplifiDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmplifiDx

What does AmplifiDx do?

AmplifiDx develops and sells a point-of-care molecular diagnostic platform (DX 100) and a portfolio of single-use assay cartridges for infectious disease detection. The platform delivers PCR-grade accuracy in under 20 minutes with less than one minute of hands-on time and can detect up to 10 analytes simultaneously from a single sample. Target users are healthcare providers in community clinics, physician offices, and urgent care centers; products are not yet FDA cleared or approved.

Is AmplifiDx a public or private company?

AmplifiDx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AmplifiDx founded?

AmplifiDx was founded in 2020. It employs 11 to 50 people.

Where is AmplifiDx based?

AmplifiDx is headquartered in Newark, United States, in the North America region.

How does AmplifiDx make money?

Two revenue lines are on record. Diagnostic Platform Hardware is the primary driver. The others are diagnostic Assay Consumables.

Who are AmplifiDx's main competitors?

Direct peers on record are Qiagen, BioMérieux and Cepheid (Danaher). Emerging players are Visby Medical, Cue Health and Talis Biomedical. Broad incumbents are Abbott, Roche Diagnostics and QuidelOrtho. Mesa Labs is listed as an others.

Does AmplifiDx have an API?

No public API is recorded for AmplifiDx.

What industry is AmplifiDx in?

AmplifiDx's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireShepherd Ventures III portfolio company AmplifiDX Secures Added Non-Dilutive FundingAmplifiDx, a Shepherd Ventures III portfolio company, received an additional $100,000 in non-dilutive NIH funding, bringing total NIH support to approximately $5.6 million. The funds will support final development of its AmplifiDX DX 100 Platform for rapid STI diagnosis. Shepherd Ventures III plans to lead a commercialization round after FDA 510(K) clearance.FemovateMeet the StartupsAfynia Labs, AmplifiDx, Armor Medical Inc, and several other startups are developing innovative healthcare solutions targeting women’s health issues, including at-home screening tests, diagnostic devices, and support platforms. The focus is on enhancing accessibility to gynecological, maternal, and reproductive health services globally. These initiatives involve various countries such as Canada, the United States, the United Kingdom, and others in addressing specific health challenges.AmplifidxAmplifiDx Secures Additional $954,213 in Non-Dilutive Funding from NIH’s RADx Tech Program to Advance U.S. COVID-19 Testing Capabilities. — AmplifiDxAmplifiDx announced on December 3, 2024 that it received an additional $954,213 in non-dilutive funding from the NIH's RADx Tech program, bringing its total NIH funding to $4.51 million. The award supports the final development stages of the DX 100 Platform, which runs the RespiFast Test for SARS-CoV-2, influenza A and B, and RSV.